School of Medicine

Andrew J. Bierhals, MD, associate professor of radiology, has been named vice chair for quality and safety for the Mallinckrodt Institute of Radiology (MIR) at Washington University School of Medicine in St. Louis. 

A drug strategy aimed at revving up the immune system and boosting a type of immune cell known as natural killer cells appears, at least in mice, to effectively treat the skin condition eczema. A team led by the School of Medicine’s Brian S. Kim, MD, is behind the strategy.

Kathy Kniepmann, at the School of Medicine, is an inquisitive, compassionate faculty member who inspires prospective and current students in the Program in Occupational Therapy. She discusses her life, her career and her lifelong interest in learning.

Jeffrey R. Millman and his team at the Washington University School of Medicine produced human insulin-secreting beta cells from stem cells using a new efficient technique. The cells were able to rapidly cure diabetes in mice for at least nine months.

Mary Klingensmith, MD, the Mary Culver Distinguished Professor and vice chair for education in the Department of Surgery at Washington University School of Medicine in St. Louis, has been named a vice president of the American Board of Surgery.

Researchers at Washington University School of Medicine in St. Louis have found that the strain of Zika that circulated in Brazil during the microcephaly epidemic that began in 2015 was particularly damaging to the developing brain.

Samantha A. Morris, assistant professor of developmental biology and of genetics at Washington University School of Medicine in St. Louis, has received a Sloan Research Fellowship in Computational and Evolutionary Molecular Biology. Sloan Research Fellowships support promising early-career scientists.

A new study offers a road map to understanding the molecular underpinnings of endometrial cancer, which could lead to new therapies. The national research team was co-led by investigators at the School of Medicine.

The School of Medicine led an international trial evaluating whether investigational drugs could slow memory loss and cognitive decline in a rare, inherited form of Alzheimer’s disease. The trial was conducted at 24 sites in Australia, Canada, France, Spain, the United Kingdom and the United States.

Researchers at the School of Medicine have discovered that the genetic variant APOE4 – long linked to dementia – spurs the spread of harmful clumps of Parkinson’s proteins through the brain. The findings suggest that therapies that target APOE might reduce the risk of dementia for people with Parkinson’s disease.